NovAliX Partners with Kyowa Hakko Kirin
News Jan 17, 2013
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets. NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."
International Team Reconstructs Nanoscale Virus Features from Correlations of Scattered X-raysNews
An international research team have used angular correlations of X-ray snapshots from non-crystalline molecules to determine the 3D structure of important biological objects.READ MORE
Scientists Develop a Synthetic Solution to Combat Dwindling Supply of Cancer and HIV DrugNews
Supplies of a promising drug for cancer, HIV and possibly other diseases is dwindling, and scientists have struggled to extract more from the marine creatures who produce it. Now, chemists have a synthetic solution.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018